Compare TJX Companies Inc (TJX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TJX Companies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? TJX Companies Inc trades at $138.76 (market cap $152.62B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: TJX Companies Inc is far larger — about 15.1× State Street SPDR S&P Biotech ETF's market cap, and TJX Companies Inc pays a 1.38% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold TJX Companies Inc for 97 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TJX | XBI | |
|---|---|---|
Market Cap | $152.62B | $10.11B |
Volume | 8,079,794 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $168.41 | $169.55 |
52-Week Low | $122.84 | $104.99 |
Typical Hold Time | 97 Days | 38 Days |
Enterprise Value | $160.93B | — |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TJX trades at $138.75, down slightly by 0.04% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growing from $48.5B in 2022 to $56.4B in 2025, and net income margin expanding to 8.63%. Recent quarters have consistently beaten EPS expectations, and analysts project a consensus price target of $174.15, implying 28% upside. The stock is supported by robust cash flow from operations of $6.12B in 2025 and a healthy balance sheet with $5.34B in cash.
The outlook for TJX is positive, driven by earnings growth, market share gains in off-price retail, and Wall Street's strong buy consensus. Key risks include competitive pressures, consumer spending volatility, and elevated valuation multiples. The stock presents a compelling opportunity for growth-oriented investors, though near-term technical overbought conditions warrant caution.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
